AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18494634 — intervention group
Group type: EXPERIMENTAL
Intervention: Versajet Hydrosurgery System (n=22)
Number of subjects: 41
Study 18494634 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical debridement (n=19)
Number of subjects: 41
Study 16460668 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused breathing induction (15 min recorded)
Number of subjects: 0
Study 16460668 — intervention group
Group type: COMPARATOR
Intervention: Unfocused attention induction (15 min recorded)
Number of subjects: 0
Study 16460668 — intervention group
Group type: COMPARATOR
Intervention: Worry induction (15 min recorded)
Number of subjects: 0
Study 12539808 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 195
Study 12539808 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 195
Study 12539808 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 195
Study 12539808 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (all doses)
Number of subjects: 195
Study 12539808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 10766085 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study 10766085 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation combined with chemotherapy
Number of subjects: 0
Study 10766085 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery
Number of subjects: 0
Study 10766085 — intervention group
Group type: COMPARATOR
Intervention: Optimal surgery
Number of subjects: 0
Study 8793166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 3.75 mg
Number of subjects: 200
Study 8793166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 7.5 mg
Number of subjects: 200
Study 8793166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg
Number of subjects: 200
Study 8793166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1613123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg
Number of subjects: 12
Study 1613123 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 12
Study 1613123 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 12
Study 6699319 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizer therapy with metaproterenol sulfate solution 15 mg in 2.3 ml
Number of subjects: 25
Study 6699319 — intervention group
Group type: EXPERIMENTAL
Intervention: Canister therapy with metered-dose metaproterenol sulfate (total 1.95 mg)
Number of subjects: 25
Study 6699319 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer therapy and Canister therapy
Number of subjects: 25
Study 29386033 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Biportal Endoscopic (UBE) technique
Number of subjects: 141
Study 29386033 — intervention group
Group type: COMPARATOR
Intervention: Open Lumbar Microdiscectomy (OLM)
Number of subjects: 141
Study 26861468 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pharmacist review of medication (SPRM) with computerised clinical decision support software (CDSS)
Number of subjects: 737
Study 26861468 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmaceutical care
Number of subjects: 737
Study 25633683 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Number of subjects: 60
Study 25633683 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Number of subjects: 60
Study 25633683 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 24371832 — intervention group
Group type: EXPERIMENTAL
Intervention: Water extracts of Graptopetalum paraguayense (WGP, 4 g/d)
Number of subjects: 54
Study 24371832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20056852 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate drink (HI-HI) before PM exercise
Number of subjects: 10
Study 20056852 — intervention group
Group type: COMPARATOR
Intervention: Nonenergetic placebo (HI-LO) before PM exercise
Number of subjects: 10
Study 18349701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 50
Study 16568465 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma dialogue
Number of subjects: 169
Study 16568465 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma narrative
Number of subjects: 169
Study 16568465 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 169
Study 15499981 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ephedrine nosedrop, antibiotic, antihistamine, and anisodamine (10 mg twice a day)
Number of subjects: 61
Study 15499981 — intervention group
Group type: COMPARATOR
Intervention: 1% ephedrine nosedrop, antibiotic, and antihistamine
Number of subjects: 61
Study 11371794 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF with bone graft supplementation
Number of subjects: 20
Study 11371794 — intervention group
Group type: COMPARATOR
Intervention: ORIF without bone graft
Number of subjects: 20
Study 8995048 — intervention group
Group type: EXPERIMENTAL
Intervention: Free binocular virtual condition
Number of subjects: 30
Study 8995048 — intervention group
Group type: EXPERIMENTAL
Intervention: Free binocular real-world condition
Number of subjects: 30
Study 8995048 — intervention group
Group type: COMPARATOR
Intervention: Static monocular real-world condition
Number of subjects: 30
Study 8995048 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender interaction with viewing conditions
Number of subjects: 30
Study 7710217 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg plus IM Ketorolac 30 mg (Group B)
Number of subjects: 90
Study 7710217 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 2 mg plus IM placebo (Group A)
Number of subjects: 90
Study 7710217 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline placebo plus IM Ketorolac 30 mg (Group C)
Number of subjects: 90
Study 3358237 — intervention group
Group type: EXPERIMENTAL
Intervention: Field follow-up with reminder system
Number of subjects: 820
Study 3358237 — intervention group
Group type: EXPERIMENTAL
Intervention: Field follow-up
Number of subjects: 820
Study 3358237 — intervention group
Group type: COMPARATOR
Intervention: Reminder system
Number of subjects: 820
Study 30195447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily
Number of subjects: 57
Study 30195447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 3 g once daily
Number of subjects: 57
Study 30195447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 27687369 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 45
Study 27687369 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 45
Study 27687369 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 25139873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 640
Study 23188412 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant LH (r-LH) administration during late follicular development stages
Number of subjects: 20
Study 23188412 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant LH (r-LH) administration
Number of subjects: 20
Study 20651460 — intervention group
Group type: COMPARATOR
Intervention: 15 mg Fe as ferric pyrophosphate
Number of subjects: 168
Study 20651460 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Fe as ferric pyrophosphate and 1.25 g DFAIII
Number of subjects: 168
Study 20651460 — intervention group
Group type: COMPARATOR
Intervention: 15 mg Fe as ferrous sulfate
Number of subjects: 168
Study 20651460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 19213340 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic treatment + small dose prednisone
Number of subjects: 67
Study 19213340 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic treatment + Chinese herbal medicine
Number of subjects: 67
Study 19213340 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment only (Control Group A)
Number of subjects: 67
Study 15798461 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented parenteral nutrition (GlnPN; glutamine target intake, 0.4 g kg day; n = 41)
Number of subjects: 80
Study 15798461 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (sPN; n = 39)
Number of subjects: 80
Study 12662915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl oleate (EO) at 8 g/day in a single serving (approximately 0.1 g/kg)
Number of subjects: 235
Study 12662915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl oleate (EO) at 16 g/day taken in two divided servings (approximately 0.2 g/kg)
Number of subjects: 235
Study 12662915 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 235
Study 12662915 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory parameters (comprehensive laboratory data)
Number of subjects: 235
Study 10227103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (n = 35)
Number of subjects: 64
Study 10227103 — intervention group
Group type: COMPARATOR
Intervention: Typical neuroleptics (n = 29)
Number of subjects: 64
Study 10227103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 64
Study 9081353 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) of thoracic spine and pelvis
Number of subjects: 42
Study 9081353 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 42
Study 9081353 — intervention group
Group type: COMPARATOR
Intervention: Bone scintigraphy (BS) and/or unilateral bone marrow biopsy and aspiration (BMBA)
Number of subjects: 42
Study 2071735 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant modeling alone (n = 9)
Number of subjects: 26
Study 2071735 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant modeling with mother (n = 8)
Number of subjects: 26
Study 2071735 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure control (n = 9)
Number of subjects: 26
Study 6841411 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contractions, 30 contractions a day for five weeks
Number of subjects: 4
Study 6841411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 4
Study 6841411 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (supramaximal)
Number of subjects: 4
Study 31784432 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplant (FMT)
Number of subjects: 45
Study 31784432 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 45
Study 30672238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue acupuncture combined with rehabilitation training
Number of subjects: 80
Study 30672238 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with acupuncture combined with rehabilitation training
Number of subjects: 80
Study 27230965 — intervention group
Group type: EXPERIMENTAL
Intervention: APOL1 high-risk status (having two copies of the G1 or G2 risk alleles)
Number of subjects: 622
Study 27230965 — intervention group
Group type: COMPARATOR
Intervention: APOL1 low-risk status (zero or one copy of the risk alleles)
Number of subjects: 622
Study 26712382 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐based prednisolone dosing
Number of subjects: 100
Study 26712382 — intervention group
Group type: COMPARATOR
Intervention: Body surface area‐based prednisolone dosing
Number of subjects: 100
Study 23434957 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with 1 μg/kg of clonidine in normal saline (Group BC)
Number of subjects: 80
Study 23434957 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with ketamine 0.5 mg/kg (Group BK)
Number of subjects: 80
Study 23434957 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with fentanyl 1 mcg/kg (Group BF)
Number of subjects: 80
Study 23434957 — intervention group
Group type: COMPARATOR
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine in normal saline (Group B)
Number of subjects: 80
Study 20378497 — intervention group
Group type: EXPERIMENTAL
Intervention: L-LV (100 mg/m2)
Number of subjects: 876
Study 20378497 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-LV (200 mg/m2)
Number of subjects: 876
Study 19046201 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-intensive SMBG
Number of subjects: 453
Study 19046201 — intervention group
Group type: EXPERIMENTAL
Intervention: More-intensive SMBG
Number of subjects: 453
Study 19046201 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 453
Study 15843938 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of oral antibiotics (neomycin and metronidazole) at the time of mechanical colon cleansing
Number of subjects: 300
Study 15843938 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of oral antibiotics
Number of subjects: 300
Study 15843938 — intervention group
Group type: COMPARATOR
Intervention: No oral antibiotics
Number of subjects: 300
Study 12377644 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU
Number of subjects: 254
Study 12377644 — intervention group
Group type: COMPARATOR
Intervention: PVI 5-FU plus MMC
Number of subjects: 254
Study 10605328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifidipine GITS 30 and 60 mg
Number of subjects: 51
Study 9166464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) chemotherapy for 6 months
Number of subjects: 1229
Study 9166464 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant systemic therapy
Number of subjects: 1229
Study 1932652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegic solution enriched with creatine phosphate (10 mmol/L)
Number of subjects: 40
Study 1932652 — intervention group
Group type: COMPARATOR
Intervention: Standard cardioplegic solution
Number of subjects: 40
Study 6699308 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20
Study 6699308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate
Number of subjects: 20
Study 6699308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with concurrent stereotactic radiation therapy (50 Gy in 4 fractions)
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with sequential stereotactic radiation therapy (60 Gy in 10 fractions)
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with radiation (overall)
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential lung group
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with radiation (liver metastases)
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with radiation (lung metastases)
Number of subjects: 106
Study 29464585 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-gauge histology needle (PC19)
Number of subjects: 110
Study 29464585 — intervention group
Group type: COMPARATOR
Intervention: 19-gauge standard needle (EC19)
Number of subjects: 110
Study 26934128 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed insulin lispro protamine suspension 75%/insulin lispro solution 25% (LM25) twice daily (bid)
Number of subjects: 476
Study 26934128 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin glargine plus prandial insulin lispro (IGL), once daily
Number of subjects: 476
Study 24518147 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical rehabilitation program (EPRP)
Number of subjects: 70
Study 24518147 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study 23046566 — intervention group
Group type: EXPERIMENTAL
Intervention: JUC (nanotechnology antimicrobial spray)
Number of subjects: 1150
Study 23046566 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 1150
Study 20167143 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 micrograms x 2 inhalations (320/9 micrograms; n = 124)
Number of subjects: 187
Study 20167143 — intervention group
Group type: COMPARATOR
Intervention: Budesonide DPI 200 micrograms x 2 inhalations (400 micrograms; n = 63)
Number of subjects: 187
Study 21707149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 44
Study 21707149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15947981 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg; study group: n=20)
Number of subjects: 40
Study 15947981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group: n=20)
Number of subjects: 40
Study 11812509 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.2, 0.4, and 0.8 mg)
Number of subjects: 12
Study 11812509 — intervention group
Group type: COMPARATOR
Intervention: D-amphetamine (15 mg, oral)
Number of subjects: 12
Study 11812509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9509076 — intervention group
Group type: COMPARATOR
Intervention: Insulin-tolerance test (ITT)
Number of subjects: 22
Study 9509076 — intervention group
Group type: COMPARATOR
Intervention: Arg stimulation test (Arg)
Number of subjects: 22
Study 9509076 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor heat exposure before the ITT
Number of subjects: 22
Study 9509076 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to hospital on the morning of the test
Number of subjects: 22
Study 9509076 — intervention group
Group type: COMPARATOR
Intervention: Plasma glucagon response
Number of subjects: 22
Study 9509076 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucagon response after hospital admission
Number of subjects: 22
Study 9509076 — intervention group
Group type: COMPARATOR
Intervention: Serum cortisol response
Number of subjects: 22
Study 7980356 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure to various fear domains (heights, transportation, social situations)
Number of subjects: 25
Study 7980356 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure sessions
Number of subjects: 25
Study 2647495 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 50 mg t.i.d.
Number of subjects: 12
Study 2647495 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 75 mg t.i.d.
Number of subjects: 12
Study 2647495 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29174683 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su administered 0, 6-month schedule
Number of subjects: 354
Study 29174683 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su administered 0, 12-month schedule
Number of subjects: 354
Study 29174683 — intervention group
Group type: COMPARATOR
Intervention: Control group (0, 2-month schedule)
Number of subjects: 354
Study 29174683 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosing intervals
Number of subjects: 354
Study 26294706 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health and substance abuse treatments for at least the first 3 years
Number of subjects: 150
Study 25763129 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized prerecorded video program on weight reduction
Number of subjects: 130
Study 25763129 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive weight reduction program
Number of subjects: 130
Study 23608784 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 571
Study 23608784 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 571
Study 20736036 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 19102187 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative reduction plus lumbar traction and various physiotherapies
Number of subjects: 11128
Study 19102187 — intervention group
Group type: COMPARATOR
Intervention: Lumbar traction and various physiotherapies
Number of subjects: 11128
Study 16902796 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate low-fat diet (HC)
Number of subjects: 11
Study 16902796 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet with additional fat (HCF)
Number of subjects: 11
Study 16902796 — intervention group
Group type: COMPARATOR
Intervention: Simulated 20-km time-trial after both diets
Number of subjects: 11
Study 12828749 — intervention group
Group type: EXPERIMENTAL
Intervention: TL-01 UVB
Number of subjects: 28
Study 12828749 — intervention group
Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 28
Study 11024413 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal confluent laser photocoagulation
Number of subjects: 70
Study 11024413 — intervention group
Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 70
Study 8711648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 31
Study 8711648 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 31
Study 8711648 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 31
Study 8711648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for indomethacin study)
Number of subjects: 31
Study 8711648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for ipratropium study)
Number of subjects: 31
Study 1352428 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1% instilled one hour before and immediately after laser treatment
Number of subjects: 60
Study 1352428 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 1% delivered only after trabeculoplasty
Number of subjects: 60
Study 1352428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 60
Study 6725520 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg oral clonidine
Number of subjects: 10